Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeutics offer new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. An enlarging base of high-quality evidence from randomized clinical trials is available to evaluate important new treatments offering organ protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. The goal of the new guideline is to provide evidence-based recommendations to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies. In addition, the guideline contains practice points to facilitate implementation when insufficient data are available to make well-justified recommendations or when additional guidance may be useful for clinical application. The guideline covers comprehensive care of patients with diabetes and CKD, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and self-management and health systems approaches to management of patients with diabetes and CKD.
Keywords: GLP-1 receptor agonist; HbA1c; KDIGO; SGLT2 inhibitor; angiotensin II receptor blocker; angiotensin-convering enzyme inhibitor; chronic kidney disease; dialysis; evidence-based; glycemia; glycemic monitoring; glycemic targets; guideline; hemodialysis; lifestyle; metformin; models of care; nutrition; renin-angiotensin system; self-management; systematic review; team-based care.
Copyright © 2020 KDIGO. Published by Elsevier Inc. All rights reserved.